1. Analysis of the prognostic factors determining the oncological outcomes in patients with high-risk early-stage cervical cancer
- Author
-
Vakkas Korkmaz, Nurettin Boran, Dilek Yüksel, Caner Cakir, Taner Turan, Osman Turkmen, Gunsu Kimyon Comert, Fatih Kilic, and Sevgi Koç
- Subjects
Oncology ,medicine.medical_specialty ,Uterine Cervical Neoplasms ,Hysterectomy ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,In patient ,Stage (cooking) ,Neoplasm Staging ,Retrospective Studies ,Cervical cancer ,030219 obstetrics & reproductive medicine ,business.industry ,Obstetrics and Gynecology ,Retrospective cohort study ,Chemoradiotherapy, Adjuvant ,High risk factors ,Prognosis ,medicine.disease ,humanities ,030220 oncology & carcinogenesis ,Female ,Radiotherapy, Adjuvant ,Neoplasm Recurrence, Local ,business - Abstract
We aimed to evaluate clinicopathological data in high-risk early-stage cervical cancer and to define the prognostic factors determining the oncological outcomes. This retrospective study included 158 patients with stage IB-IIA cervical cancer who underwent radical hysterectomy plus lymph node dissection. Each patient had at least one high-risk factor. The median tumour diameter of the study group was 30 mm (range, 6-80). Seventy-five (47.5%) patients had parametrial invasion, 32 (20.3%) had positive surgical margins, and 108 (68.4%) had lymph node metastasis. The median duration of follow-up was 42 months (range, 1-228). During this period, 28 patients developed recurrence, and the recurrent disease occurred in a distant area in 18 patients. Five-year disease-free survival was 77.5%, and five-year disease-specific survival was 85%. In multivariate analysis, adjuvant radiotherapy was identified as an independent prognostic factor for recurrence and death. The recurrence (Odds ratio: 10.139, 95% CI: 1.477-69.590
- Published
- 2021
- Full Text
- View/download PDF